



Ain Shams University  
Faculty of Science  
Chemistry Department



# **Radiochemical and Biological Characterization of some Radiolabeled Drugs for Nuclear Medicine Applications**

Thesis submitted for the degree of PhD in Chemistry

Presented by

**Mai Adel Abd Ellatif Mourad**

B.Sc. (Chemistry / Zoology) 2010

M.Sc. (Analytical Chemistry) 2014

Supervised by

**Prof. Dr. Salah Abdel Ghani Abo-El-Enein**

Professor of Physical Chemistry, Faculty of Science, Ain Shams University

**Prof. Dr. Gehad Genidy Mohamed**

Professor of Inorganic and Analytical Chemistry, Faculty of Science, Cairo  
University

**Prof. Dr. Abeer Mohamed Amin**

Professor of Radiochemistry, Hot Labs Center, Egyptian Atomic Energy  
Authority

**Dr. Hanan Abd El-Azez Abd El-Razk Elsabagh**

Lecturer of Radiochemistry, Hot Labs Center, Egyptian Atomic Energy  
Authority

**2018**





**Ain Shams University**  
**Faculty of Science**  
**Chemistry Department**



## **Approval Sheet**

### **Radiochemical and Biological Characterization of some Radiolabeled Drugs for Nuclear Medicine Applications**

A Thesis Submitted By  
**Mai Adel Abd Ellatif Mourad**  
For Ph.D. Degree in Chemistry

This thesis has been approved by:

**Prof. Dr. Salah Abdel Ghani Abo-El-Enein**

Professor of Physical Chemistry, Faculty of Science, Ain Shams University

**Prof. Dr. Gehad Genidy Mohamed**

Professor of Inorganic and Analytical Chemistry, Faculty of Science, Cairo University

**Prof. Dr. Abeer Mohamed Amin**

Professor of Radiochemistry, Hot Labs Center, Egyptian Atomic Energy Authority

**Dr. Hanan Abd El-Azez Abd El-Razk Elsabagh**

Lecturer of Radiochemistry, Hot Labs Center, Egyptian Atomic Energy Authority

Head of Chemistry Department  
**Prof. Dr. Ibrahim Hosiny Ali Badr**



# *The Acknowledgement*

*Above all, praise to ALLAH almighty, my god, my lord, for his grace and blessing and for not leaving me in the hardest times.*

*My deep thanks to **Prof. Dr. Abeer Mohamed Amin**, Professor of Radiochemistry, Hot Labs Center, Egyptian Atomic Energy Authority, for continues guidance, valuable and fruitful comments and discussions over the whole duration of the study.*

*The author is also greatly indebted to **Dr. Hanan Abd El-Azez Abd El-Razk Elsabagh**, Lecturer of Radiochemistry, Hot Labs Center, Egyptian Atomic Energy Authority, for suggesting the problem, direct supervision and kind help during the experimental work and theoretical calculation.*


*I express my sincere gratitude to **Prof. Dr. Salah Abdel Ghani Abo-El-Enein**, Professor of Physical Chemistry, Faculty of Science, Ain Shams University, and **Prof. Dr. Gehad Genidy Mohamed**, Professor of Inorganic and Analytical Chemistry, Faculty of Science, Cairo University, for their guidance during the progress of this work.*

*I would like to appreciate **Prof. Dr. Doaa Farouk**, Professor at Animal Production Research Institute, for introducing me all the facilities to achieve this work.*

*Many thanks are also directed to **Dr. Sherif Eltamimy**, Physicist at Centre of Radiation Oncology and Nuclear Medicine, Kasr Al-Ainy, for his assistance and cooperation in imaging procedure.*

***Mai Mourad***





## Radioiodination and Biological Evaluation of Tizanidine as a Potential Brain Imaging Agent

M.A. Mourad<sup>a</sup>, H. Abd El-Aziz<sup>b</sup>, A.M. Amin<sup>b</sup>, G.G. Mohamed<sup>c</sup> and S.A. Abo El-Enein<sup>d</sup>

<sup>(a)</sup>Centre of Radiation Oncology and Nuclear Medicine, Kasr Al-Ainy, Cairo, Egypt

<sup>(b)</sup>Labeled Compounds Department, Hot Labs Center, Atomic Energy Authority, Cairo, Egypt

<sup>(c)</sup>Chemistry Department, Faculty of Science, Cairo University, 12613, Giza, Egypt

<sup>(d)</sup>Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt

Received 1<sup>st</sup> May 2017  
Accepted 1<sup>st</sup> Jan. 2018

Labeling was carried out by direct iodination of tizanidine (100 µg) with radioiodine (<sup>125</sup>I) in a fast single step at room temperature, to produce <sup>125</sup>I-tizanidine (<sup>125</sup>I-TZN). 50 µg chloramine-T (CAT) was used as an oxidizing agent to oxidize the iodide ion to the iodonium ion, at neutral pH = 7 within 15 min. A high radiochemical yield of 92.8 % ± 0.1 was obtained. <sup>125</sup>I-TZN was stable for 2 h without detection of any by-products in the reaction mixture. The partition coefficient value of <sup>125</sup>I-TZN was 2.21 ± 0.02, showing that it is very lipophilic and can easily cross the blood brain barrier. Biodistribution studies and *in vivo* imaging showed that the initial brain uptake correlated fairly well with the brain-binding affinity of the compound. The brain uptake of <sup>125</sup>I-TZN was as high as 5.2 % and 8.0 % in biodistribution studies and *in vivo* imaging at 120 min post injection, respectively. Thus, <sup>125</sup>I-TZN is promising in radioreceptor assays for brain imaging.

**Keywords:** Radioiodination - Tizanidine - Biodistribution- Brain Imaging - SPECT

### Introduction

Nuclear medicine imaging involves the detection and spatial mapping of the radiation emitted by a radiopharmaceutical labeled with a specific radionuclide. The objectives of a nuclear medicine scan of the brain may include, for example, the detection of lesions, the evaluation of regional cerebral blood flow (rCBF), or the quantitative determination of a particular metabolic process such as the rate of regional glucose utilization [1]. The development of emission tomography is a good example of the fusion of a number of scientific and medical disciplines to produce an effective imaging technique. There are two different techniques of emission tomography:

positron emission tomography (PET), based on radionuclides which decay by positron emission, and single photon

emission computed tomography (SPECT) which is based on radionuclides which emit gamma rays or X-rays. While PET has some inherent technical advantages over SPECT, the economic reality dictates that SPECT is usually the only technique available in routine clinical practice. Recent innovations in the design of multi-head SPECT systems, which allow them to detect positron-emitting radionuclides, have diminished the sharp distinction between the two techniques [2].

Corresponding Author: [mai.adel89@gmail.com](mailto:mai.adel89@gmail.com)

DOI: [10.21608/ajnsa.2018.2178.1017](https://doi.org/10.21608/ajnsa.2018.2178.1017)

© Scientific Information, Documentation and Publishing Office (SIDPO)-EAEA



**LIST OF ABBREVIATIONS**

<i>Abbreviation</i>	<i>Item</i>
EC	electron capture
IT	isomeric transition
LET	linear energy transfer
CAT	chloramine-T
SPECT	single-photon emission computed tomography
PET	positron emission tomography
BBB	blood-brain barrier
CT	computed tomography
FDG	fluorodeoxyglucose
rCBF	regional cerebral blood flow
TZN	tizanidine
QTP	quetiapine
CBP	cyclobenzaprine
NPs	nanoparticles
NODCAR	National Organization for Drug Control and Research
BDH	British Drug Houses
SG-TLC	silica gel thin-layer chromatography
HPLC	high-performance liquid chromatography
HEGAP-Par	high energy general all purpose-parallel
Br	brain
Bl	blood
GIT	gastrointestinal tract
fMRI	functional magnetic resonance imaging

## **ABSTRACT**

**Candidate Name:** Mai Adel Abd Ellatif Mourad

**Title of Thesis:** Radiochemical and Biological Characterization of some Radiolabeled Drugs for Nuclear Medicine Applications

**Degree (PhD):** The PhD of Science in Chemistry, Faculty of Science, Ain Shams University, 2018.

This study aimed to take advantages from drugs that are able to cross the blood-brain barrier for the development of potential radiopharmaceuticals for non-invasive brain imaging. Tizanidine hydrochloride, quetiapine fumarate and cyclobenzaprine hydrochloride were successfully labeled with radioactive iodine ( $^{125}\text{I}$ ) using chloramine-T via an electrophilic substitution reaction.  $^{125}\text{I}$ -tizanidine,  $^{125}\text{I}$ -quetiapine and  $^{125}\text{I}$ -cyclobenzaprine gave maximum labeling yields of  $92.8 \% \pm 0.1$ ,  $94.5 \% \pm 1.5$  and  $91.7 \% \pm 0.6$ , respectively. Biodistribution studies showed that the maximum uptake of radioiodinated tizanidine and quetiapine by the brain of mice was  $5.2 \%$  and  $3.5 \%$ , respectively, at 120 min post injection while the maximum uptake of radioiodinated cyclobenzaprine was  $2.9 \%$  at 240 min post injection. The SPECT imaging confirmed the results of biodistribution studies.

**Keywords:** Radiopharmaceuticals, Radioiodination, Tizanidine, Quetiapine, Cyclobenzaprine, Brain imaging, Biodistribution, SPECT.

**LIST OF CONTENTS**

<i>Subject</i>	<i>Page No.</i>
<b>CHAPTER I: INTRODUCTION AND OBJECT OF INVESTIGATION</b>	
<b>IA. INTRODUCTION</b>	<b>1</b>
<b>IA.1. Radioactivity</b>	<b>1</b>
<b>IA.2. Types of Radioactivity</b>	<b>1</b>
<b>IA.3. Radionuclides</b>	<b>2</b>
<b>IA.4. Radiopharmaceuticals</b>	<b>4</b>
<b>IA.5. Types of Radiopharmaceuticals</b>	<b>5</b>
<b>IA.6. Characteristics of Ideal Radiopharmaceuticals</b>	<b>7</b>
<b>IA.7. Quality Control of Radiopharmaceuticals</b>	<b>11</b>
<b>IA.8. Iodine</b>	<b>11</b>
<b>IA.9. Radioactive Waste</b>	<b>19</b>
<b>IA.10. Treatment of Biomedical Radioactive Waste</b>	<b>19</b>
<b>IA.11. Nuclear Medicine</b>	<b>22</b>
<b>IA.12. Human Brain</b>	<b>22</b>
<b>IA.13. Brain Imaging in Nuclear Medicine</b>	<b>29</b>
<b>IA.14. Radiopharmaceuticals for Brain Imaging</b>	<b>36</b>
<b>IA.15. Tizanidine Hydrochloride</b>	<b>38</b>
<b>IA.16. Quetiapine Fumarate</b>	<b>39</b>
<b>IA.17. Cyclobenzaprine Hydrochloride</b>	<b>40</b>
<b>IA.18. Literature Survey</b>	<b>41</b>
<b>IB. OBJECT OF INVESTIGATION</b>	<b>43</b>

<i>Subject</i>	<i>Page No.</i>
<b>CHAPTER II: MATERIALS AND METHODS OF INVESTIGATION</b>	
<b>IIA. MATERIALS</b>	<b>44</b>
<b>IIA.1. Chemicals</b>	<b>44</b>
<b>IIA.2. Equipment</b>	<b>45</b>
<b>IIA.3. Animals</b>	<b>46</b>
<b>IIA.4. Buffers</b>	<b>47</b>
 <b>IIB. METHODS OF INVESTIGATION</b>	 <b>49</b>
<b>IIB.1. Radioiodination</b>	<b>49</b>
<b>IIB.2. Determination of Radiochemical Yield</b>	<b>49</b>
<b>IIB.3. Factors Affecting Radiochemical Yield</b>	<b>50</b>
<b>IIB.4. <i>In vitro</i> Stability</b>	<b>53</b>
<b>IIB.5. Determination of Partition Coefficient</b>	<b>53</b>
<b>IIB.6. Determination of Radiochemical Purity</b>	<b>54</b>
<b>IIB.7. <i>In vivo</i> Biodistribution Studies</b>	<b>54</b>
<b>IIB.8. <i>In vivo</i> SPECT Imaging of TZN</b>	<b>55</b>
<b>IIB.9. <i>In vivo</i> SPECT/CT Imaging of QTP and CBP</b>	<b>56</b>
 <b>CHAPTER III: RESULTS AND DISCUSSION</b>	
<b>III.1. Effect of Substrate Concentration</b>	<b>57</b>
<b>III.2. Effect of CAT Concentration</b>	<b>60</b>
<b>III.3. Effect of Reaction Temperature</b>	<b>63</b>
<b>III.4. Effect of pH of Reaction Medium</b>	<b>66</b>
<b>III.5. Effect of Reaction Time</b>	<b>69</b>
<b>III.6. <i>In vitro</i> Stability</b>	<b>72</b>

<i>Subject</i>	<i>Page No.</i>
<b>III.7.</b> Lipophilicity	<b>74</b>
<b>III.8.</b> HPLC Analyses	<b>74</b>
<b>III.9.</b> Biodistribution Studies	<b>77</b>
<b>III.10.</b> <i>In vivo</i> SPECT Imaging of TZN	<b>83</b>
<b>III.11.</b> <i>In vivo</i> SPECT/CT Imaging of QTP and CBP	<b>84</b>
 <b>CHAPTER IV: SUMMARY AND CONCLUSIONS</b>	
<b>IVA.</b> SUMMARY	<b>87</b>
<b>IVB.</b> CONCLUSIONS	<b>91</b>
 <b>REFERENCES</b>	 <b>92</b>
<b>ARABIC SUMMARY</b>	

---

## LIST OF TABLES

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table 1.</b>	Examples of radiopharmaceuticals used as diagnostic agents.	<b>6</b>
<b>Table 2.</b>	Examples of radiopharmaceuticals used as therapeutic agents.	<b>7</b>
<b>Table 3.</b>	Nuclear characteristics of the main radioisotopes of iodine.	<b>13</b>
<b>Table 4.</b>	Neurotransmitter receptors and related binding sites that have been examined by autoradiography in the human brain.	<b>28</b>
<b>Table 5.</b>	<i>In vitro</i> stability of $^{125}\text{I}$ -TZN, $^{125}\text{I}$ -QTP and $^{125}\text{I}$ -CBP at optimum labeling conditions.	<b>73</b>
<b>Table 6.</b>	Biodistribution of $^{125}\text{I}$ -TZN in normal mice at different times.	<b>80</b>
<b>Table 7.</b>	Biodistribution of $^{125}\text{I}$ -QTP in normal mice at different times.	<b>81</b>
<b>Table 8.</b>	Biodistribution of $^{125}\text{I}$ -CBP in normal mice at different times.	<b>82</b>
<b>Table 9.</b>	The injected dose percentage of $^{131}\text{I}$ -TZN in some organs according to SPECT imaging.	<b>84</b>
<b>Table 10.</b>	The injected dose percentage of $^{131}\text{I}$ -QTP in some organs according to SPECT/CT imaging.	<b>86</b>
<b>Table 11.</b>	The injected dose percentage of $^{131}\text{I}$ -CBP in some organs according to SPECT/CT imaging.	<b>86</b>

**LIST OF FIGURES**

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure 1.</b>	The main parts of the human brain.	<b>23</b>
<b>Figure 2.</b>	Scintillation gamma camera.	<b>31</b>
<b>Figure 3.</b>	Parathyroid planar scan image.	<b>31</b>
<b>Figure 4.</b>	PET/CT gamma camera.	<b>33</b>
<b>Figure 5.</b>	Whole body PET scan image.	<b>33</b>
<b>Figure 6.</b>	SPECT gamma camera.	<b>35</b>
<b>Figure 7.</b>	Brain SPECT scan image.	<b>36</b>
<b>Figure 8.</b>	Chemical structure of TZN hydrochloride.	<b>39</b>
<b>Figure 9.</b>	Chemical structure of QTP fumarate.	<b>40</b>
<b>Figure 10.</b>	Chemical structure of CBP hydrochloride.	<b>41</b>
<b>Figure 11.</b>	The radiochemical yields of $^{125}\text{I}$ -TZN as a function of substrate amount.	<b>58</b>
<b>Figure 12.</b>	The radiochemical yields of $^{125}\text{I}$ -QTP as a function of substrate amount.	<b>59</b>
<b>Figure 13.</b>	The radiochemical yields of $^{125}\text{I}$ -CBP as a function of substrate amount.	<b>60</b>
<b>Figure 14.</b>	The radiochemical yields of $^{125}\text{I}$ -TZN as a function of CAT amount.	<b>61</b>
<b>Figure 15.</b>	The radiochemical yields of $^{125}\text{I}$ -QTP as a function of CAT amount.	<b>62</b>
<b>Figure 16.</b>	The radiochemical yields of $^{125}\text{I}$ -CBP as a function of CAT amount.	<b>63</b>
<b>Figure 17.</b>	Effect of temperature on the radiochemical yield of $^{125}\text{I}$ -TZN.	<b>64</b>
<b>Figure 18.</b>	Effect of temperature on the radiochemical yield of $^{125}\text{I}$ -QTP.	<b>65</b>